BioCina is a biologics contract development and manufacturing organization (CDMO) that provides scientific and operational services for the development and manufacture of microbial, pDNA, and mRNA-based vaccines.

BioCina

NovaCina is a contract development and manufacturing organization (CDMO) in Australia that offers sterile liquid pharmaceutical contract manufacturing services, including technical and analytical support.

NovaCina

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

Sandoz Group AG

Vetter is a family-owned, award-winning, high-performance service provider for the global pharmaceutical and biotech industry. Specializing in aseptic filling of customers’ drug products in syringes, cartridges, and vials, Vetter partners with its customers from clinical development through regulatory approval, market launch, and beyond. The company is committed to sustainability, carbon neutrality, and aligning its efforts with the United Nations' 17 Sustainable Development Goals (SDGs). With over 6,300 employees worldwide, Vetter focuses on producing customer products that improve people's lives.

Helmut Vetter

Vetter

BioCina | 4,604 followers on LinkedIn. Global end-to-end biologics CDMO, offering process development and cGMP clinical and commercial manufacturing | BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical &amp; commercial manufacturing of the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of its work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s with an average tenure of 15+ years at the site.

Chief Executive Officer at BioCina and Member of Board of Directors for NovaCina and LumaCina

Mark W. Womack

Business Development Director l Building Strategic Alliances & Driving Growth for Better Patient Outcomes

Rik Quaghebeur

Project Manager | Pharmaceuticals & Biotech professional | Supporting Healthcare & Life Sciences growth and innovation to improve people's lifes

Karla Riquelme Barrera

Vice President, Business Development and Commercial Operations

Jan Bekker

Recapping BioCina at AusBiotech 2024 Last week, some members of our Business Development team, including CEO Mark W. Womack , VP of Business Development & Commercial Operations Jan Bekker , and Sales Specialist Vanessa Kee , had the opportunity to attend AusBiotech 2024 in Melbourne. It was great to meet with current and future clients and partners as well as industry leaders in the Australian and broader biotech community. Our CEO Mark W. Womack shared his insights during a panel hosted by Cytiva on “Bridging the Valley: From Bench to Early Phase.” Joined by Helen Benham from Translational Research Institute Australia and Patrick James from CSIRO . They discussed their perspectives on advancing discovery research in the Australian ecosystem. Mark also shared further strategies for researchers bringing their new therapeutics into the market. A big thank you to everyone in the Australian and international biotech industry that we engaged with. We look forward to more ahead! Check out some highlights from the panel session and our team’s interactions at the event! 📸 #BioCina #AusBiotech2024 #Biotech #CDMO #Innovation #Partnerships

Exciting insights from our CEO, Mark W. Womack , in an interview with Nigel Walker ! Mark shares BioCina's achievements so far and a look into our bright future as we expand further in #Biopharma across #Australia . Check out the full interview to hear more about BioCina’s commitment to innovation and excellence! #BioCina #CDMO #Biopharma #LifeSciences #Innovation #Australia #Growth

BioCina is headed to AusBiotech 2024! We’re excited to announce that both Mark W. Womack , CEO of BioCina, and Jan Bekker , VP of Business Development & Commercial Operations, will be attending the largest life sciences event in Australia — #AusBiotech2024 from October 30th to November 1st in Melbourne! Don’t miss the opportunity to connect with Mark and Jan about BioCina's industry-leading CDMO services! In addition, Mark W. Womack will be sharing his insights as part of an expert panel hosted by Cytiva at 2:20PM-3:05PM on Thursday October 31st, discussing "Bridging the valley: From bench to early phase." 📩 Reach out to Mark ( mwomack@biocina.com ) or Jan ( jbekker@biocina.com ) to set up a meeting during the conference. See you in Melbourne! #BioCina #AusBiotech2024 #LifeSciences #BiotechInnovation #Biologics #CDMO #Partnerships #Australia

We’re proud to announce that Mark W. Womack , CEO of BioCina, will be attending and speaking at #AusBiotech2024 , Australia’s largest Life Sciences Conference in Melbourne from October 30th to November 1st! Joining him will be Jan Bekker , our VP of Business Development & Commercial Operations, as we engage with the global biotech community. Mark will be part of an expert panel hosted by Cytiva , sharing invaluable insights on bridging the gap from early-phase clinical trials to commercial success – a pivotal step in advancing human health. We look forward to discussing innovation, our CDMO Programs, and exploring new partnership opportunities. If you’re attending #AusBiotech2024 , be sure to connect with Mark and Jan! ✉️ mwomack@biocina.com ✉️ jbekker@biocina.com #LifeSciences #Biotech #Innovation #BiologicsCDMO #Partnerships #BioCina #Australia #CommercialOperations

Dear All, Please see this very exciting news directly from our CEO, Mark W. Womack ! #SAPremiersBusinessandExportAwards #BioCina #SABusinessChamber #BiologicsCDMO #Microbial #pDNA #mRNA

🌟 Press Release 🌟 We're thrilled to announce that Centivax has selected BioCina as their partner for cGMP manufacturing in the development of their revolutionary universal influenza vaccine, Cent-Flu. This innovative vaccine has demonstrated the ability to provide protection against current, past, and future influenza strains. BioCina’s Chief Executive Officer, Mark W. Womack stated, “We're privileged to support Centivax’s breakthrough approach to sustained flu prevention and we couldn’t be more excited to be their partner of choice to initiate cGMP manufacturing, thus advancing the journey to bring such an important vaccine to market. This is a tremendous opportunity for the BioCina Team to leverage our world-class capabilities in cell line development, cell banking, and cGMP plasmid production." For more details, check out the full press release here ➡ https://lnkd.in/djUSwUiH #BioCina #Centivax #UniversalFluVaccine #CDMO #Biologics #GMP #Vaccines #Innovation #Healthcare #Biotechnology #CentFlu

We are looking for a qualified and skilled Finance Manager with proven leadership experience and a solid understanding of financial management. Join us to make a significant impact.

📢 PR Release: EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment. We are excited to announce a new partnership with drug developer EnGeneIC , for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC’s proprietary ‘EnGeneIC Dream Vector’ (EDV™) nanocells. Our Chief Executive Officer, Mark W. Womack stated, “I’m so very proud for BioCina to be entrusted to advance EnGeneIC’s transformative therapeutic, which has the potential to make a profound impact on previously untreatable cancers.” For more information please see the full press release here 👉 https://lnkd.in/gMyh4Sae

BioCina offers end-to-end #mRNA contract development and manufacturing services. Our expert team brings extensive technical experience in plasmid manufacturing, in-vitro transcription, purification, and LNP encapsulation of mRNA products. We also offer single site solutions for analytical method development, method validation, product characterisation packages and stability studies. To learn more, view our Fact Sheet below for an overview of our mRNA development and clinical and commercial manufacturing services. Contact us today 🤝 https://lnkd.in/eGSsWhnm or info@biocina.com #CDMO #biologics #plasmiddna #pDNA #messengerRNA #microbial

We are thrilled to be GenomeFrontier Therapeutics, Inc. #CDMO partner for their highly innovative CAR-T therapy program, supporting them with process development and GMP manufacturing for minicircle DNA (for transient gene expression) and Plasmid DNA. Through our current work with them, we are very proud that we recently became the only CDMO to have scaled minicircle DNA manufacturing up to large scale and to have to have successfully manufactured GMP batches! Read more on the partnership here: https://lnkd.in/eemaCr2z Learn more about our recent announcement around minicircle DNA technology here: https://lnkd.in/g6ScC-9Q 🚀 Ready to scale-up your science? Let’s partner up! Contact us today: info@biocina.com . #CAR -T #plasmidDNA #pDNA #minicircleDNA #mcDNA #transientgeneexpression

Metric
Company Name	BioCina	NovaCina	Sandoz Group AG	Vetter
Symbol			SDZ
MSH ID	COM:BIOCINA	CO:NOVACINA	COM:SANDOZ	COM:VETTER-PHARMA
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Pharmaceuticals	Pharmaceuticals	Drug Manufacturers - Specialty & Generic	Pharmaceutical and Biotech
Country	AU	AU	CH
Stage
Employee Count	101		22.63K	5.00K
Website	biocina.com	novacina.co	sandoz.com	vetter-pharma.com
LinkedIn	biocina		sandoz
Founders

Metric
Market Cap		17.15B
Enterprise Value
Monthly Web Traffic	13.54K	70.57K
Web Traffic Growth	1.75	-0.53
Valuation
Raised Capital		667.33M

Metric
Revenue			10.19B
Revenue (LTM)
Revenue (NTM)
Gross Profit			4.64B
EBITDA			1.79B
Operating Income			1.26B
Net Income			78.88M
EPS			0.18
Diluted EPS			0.18
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.46
Operating Profit Margin			0.12
EBITDA Margin			0.18
Net Profit Margin			0.01
Return on Equity			0.02
Return on Assets			0.00
Return on Capital Employed			0.10

BIOC

COM:BIOCINA

BioCina

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-546.36K
P/B Ratio			161.92K
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			2.11
EV Multiple			24.63

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding			198.03
Operating Cycle			296.56
Cash Conversion Cycle			186.04
Asset Turnover			0.55

Metric
Operating Cash Flow			370.83M
Free Cash Flow			-276.59M
Cash Flow to Debt			0.12
Operating Cash Flow/Sales			0.05
Free Cash Flow Yield

Metric
Cash & Equivalents			1.06B
Accounts Receivable			-309.37M
Inventory			2.59B
Goodwill			7.28B
Debt to Capitalization			0.34
Debt to Assets
Current Ratio			4.37
Quick Ratio			0.86

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue